The randomised, double-blind, placebo-controlled Phase I Study evaluated the safety, tolerability and pharmacokinetic profile of NRM8499, compared to tramiprosate in 67 young and elderly healthy subjects.
The study results showed that NRM8499 was safe and well tolerated at the intended therapeutic dose.
In addition, gastrointestinal ability and pharmacokinetic profile of tramiprosate were meaningfully improved with the administration of NRM8499, when compared to an equal dose of tramiprosate.
Bellus Health president and CEO Roberto Bellini said the company is pleased with the results of the NRM8499 phase I clinical study.
"The results show a solid potential for pursuing NRM8499 for the treatment of Alzheimer’s disease," Bellini said.